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Human Papillomavirus (HPV) is the most common sexually transmitted virus. Worldwide, the most common
high-risk (HR)-HPV are -16/18, and approximately 70% of cervical cancers (CC) are due to infection by these
genotypes. Persistent infection by HR-HPV is a necessary but not sufficient cause of this cancer, which develops
over a long period through precursor lesions, which can be detected by cytological screening. Although this
screening has decreased the incidence of CC, HPV-related cervical disease, including premalignant and malignant
lesions, continues to be a major burden on health-care systems. Although not completely elucidated, the
HPV-driven molecular mechanisms underlying the development of cervical lesions have provided a number of
potential biomarkers for both diagnostic and prognostic use in the clinical management of women with
HPV-related cervical disease, and these biomarkers can also be used to increase the positive predictive value of
current screening methods. In addition, they can provide insights into the biology of HPV-induced cancer and thus
lead to the development of nonsurgical therapies. Considering the importance of detecting HPV and related
biomarkers, a variety of methods are being developed for these purposes. This review summarizes current
knowledge of detection methods for HPV, and related biomarkers that can be used to discriminate lesions with a
high risk of progression to CC.
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Human Papillomavirus (HPV) is the most common
sexually transmitted virus [1]. There are around 100
types of HPV, with different variations in their genetic
and oncogenic potential [2]. Cervical cancer (CC) is
caused by types of HPV that belong to a few phylogenet-
ically related “high-risk” (HR) species (alpha-5, 6, 7, 9,
11) of the mucosotropic alpha genus [3,4]. The types
found most frequently in CC (-16, -18, -31, -33, -35, -45,
-52, -58) and four less-common types (-39, -51, -56, -59)
were classified in Group 1. The remaining types of HPV
in the HR alpha species were classified as “possibly car-
cinogenic” (Group 2. 2A: -68; 2B: -26, -30, -34, -53, -66,
-67, -69, -70, -73, -82, -85, -97). Finally, HPV -6 and -11,
which belong to the alpha-10 species, were “not classifi-
able as to their carcinogenicity in humans” (Group 3) [5]
and were also described as “low risk” (LR) [6].* Correspondence: melconsolaro@gmail.com
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reproduction in any medium, provided the orWorldwide, the most common HR-HPV are -16/18,
and approximately 70% of CC are due to these geno-
types. LR-HPV, principally -6/11, are predominantly
involved in the development of genital warts [6]. CC is
the second most common cancer in women worldwide,
and is a major cause of morbidity and mortality [7]. Per-
sistent infection with HR-HPV is a necessary but not
sufficient cause of this cancer, which develops over a
long period of time through precursor lesions, which
can be detected by cytological screening. The majority of
these lesions regress spontaneously without treatment.
The challenge of CC screening is to detect the lesions
that have a high risk of progression [8,9].
Although cervical cytology screening has decreased the
incidence of CC, HPV-related cervical disease, including
premalignant and malignant lesions, continues to repre-
sent a major burden on health-care systems. Some of the
problems include the potential for either under- or over-
treatment of women, due to low specificity of screening
tests, as well as to significant variability in the diagnosis
of cervical dysplastic lesions. Although not completelytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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underlying the development of cervical lesions have pro-
vided a number of potential biomarkers for both diagnos-
tic and prognostic use in the clinical management of
these women, and have increased the positive predictive
value of current screening methods [10].
Considering the importance of detection of HPV and
related biomarkers, several methods are being developed
for these purposes. This review summarizes current
knowledge about detection methods for HPV and related
biomarkers that can be used to discriminate lesions with
a high risk of progression to CC.
Molecular methods for HPV detection
HPV cannot be propagated in tissue culture, and there-
fore, in most cases its accurate identification relies on
molecular biology techniques. With a double-stranded
DNA genome of about 8000 base pairs (bp) and a well-
known physical structure and gene organization, the
tests of choice for detecting HPV in clinical specimens
are based on nucleic probe technology [11] (Figure 1).
The six main possible clinical applications of HPV
DNA testing are: (i) triage of women with equivocal or
low-grade cytological abnormalities; (ii) follow-up of
women with abnormal screening results who are nega-
tive at colposcopy/biopsy; (iii) prediction of the thera-
peutic outcome after treatment of cervical intraepithelial
neoplasia (CIN); (iv) primary screening for HPV DNAFigure 1 Genome organization of HPV. Location of the HPV
major proteins. The HPV genome encodes early proteins with
regulatory (E1 and E2) and transforming (E6 and E7) functions and
two late capsid proteins (L1 and L2). Protein E4 has a largely
unknown function and E5 is a hydrophobic protein that enhances
cell immortalization. Adapted from Faridi R, Zahra A, Khan K, Idrees
M. Virol J. 2011; 8:269.testing, alone or in combination with a Pap smear, to de-
tect cervical-cancer precursors [12]; (v) gain valuable in-
formation on the persistence of certain HPV types [13];
and (vi) investigations of regional and country-based
prevalence of type-specific HPV, to provide baseline
values against which the global impact of HPV vaccin-
ation can be assessed in the future [14].
Two HPV vaccines are commercially available, a bi-
valent (types -16/18) and quadrivalent (types -6, -11, -16
and 18) [15]. Vaccination against HPV-16/18 in particu-
lar can potentially prevent more than two-thirds of CC
worldwide. Promising new broad-spectrum HPV vac-
cines are in development [16]. In addition, novel strat-
egies based on the use of HPV DNA assays for primary
cervical screening are increasingly recommended [14].
The presence of HPV can be inferred from morpho-
logical, serological and clinical findings [11,17]. However,
HPV diagnosis relies on molecular-biology techniques
that allow its accurate detection and typing [18]. At
present, nucleic acid-hybridization assays, signal-
amplification assays and nucleic-acid amplification are
available (Figure 2) (Table 1).Nucleic acid-hybridization assays
Initially, techniques such as Southern blotting, in situ
hybridization, and dot-blot hybridization used radio-
labeled nucleic acid hybridization assays to detect HPV
infection in cervical samples. Although these techniques
generated high-quality information, the disadvantages of
these direct-probe approaches include low sensitivity,
the need for relatively large amounts of purified DNA,
and time-consuming procedures [11].Signal-amplification assays
The DigeneW HPV test using Hybrid CaptureW 2 (hc2)
technology, and the CervistaW HPV HR assay are the
only methods that currently have FDA (Food and Drug
Administration) approval for diagnostic testing in the
United States [19].
The Hybrid CaptureW 2 system (hc2, Digene Corp.,
USA) is a non-radioactive signal-amplification method
based on the hybridization of the target HPV-DNA to
labeled RNA probes in solution [20]. This test detects
13 HR-HPV types (-16,-18,-31,-33,-35,-39,-45,-51,-52,-
56,-58,-59 and -68) or 5 LR-types (-6, -11, -42, -43, and
-44) [19].
This assay distinguishes between HR and LR groups,
but was not designed for genotyping single HPV [19].
This is a significant finding, since with persistent infec-
tion the risk of a precancerous lesion is between 10 and
15% with HPV types -16/18, and below 3% for all other
HR types combined. Therefore, HPV genotyping is very
important to identify single oncogenic HPV types [21]
Figure 2 Schematic diagram of classification for HPV tests.
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stratification as well as persistence of infection [22,23].
The CervistaW HPV (Hologic, Inc., Marlborough, MA,
USA) detects the presence of 14 HR-HPV types, consist-
ing of -16,-18,-31,-33,-35,-39,-45,-51,-52,-56,-58,-59,-66
and -68 [19]. This assay also utilizes a signal-amplification
method for the detection of specific nucleic acids.
In comparison with hc2, the CervistaW assay demon-
strated 100% sensitivity in the detection of CIN III and
98% sensitivity in the detection of CIN II [24]. In
addition, this assay showed a lower false-positive rate,




This method uses probe amplification, the PCR (Poly-
merase chain reaction) product is hybridized onto a
chip, and after a washing step, hybridized signals are




Southern blot is gold standard for HPV genomic






High sensitivity to genotyping
Nucleic acids
amplification assays
Flexible technology (viral load and genotype)
Very high sensitivity
Multiplex analysis
HPV = Human Papillomavirus; FDA = Food and Drug Administration; hc2 = Hybrid Cmicroarray-based automated techniques allow for paral-
lel analysis of multiple DNA samples. At present, the
two major applications of DNA microarrays are gene-
expression profiling and mutation analysis [28].
Some studies have demonstrated that DNA microarray
analysis coupled with PCR can be successfully applied to
detection and genotyping of the HPV. The HPV DNA
chip showed higher sensitivity and specificity than gel
electrophoresis, and in some cases produced better
results than direct DNA sequencing [29,30].
PapilloCheckW
This assay detects and genotypes 24 HPV types in a sin-
gle reaction (HPV -6, -11, -16, -18, -31, -33, -35, -39,
-40, -42, -43, -44, -45, -51, -52, -53, -55, -56, -58, -59,
-66, -68, -70, -73, and -82). The assay uses a multiplex
PCR with fluorescent primers to amplify a 350 bp frag-
ment of the E1 gene of HPV, comprising 28 probes, each
in 5 replicate spots fixed on a DNA chip. Co-
amplification of the human ADAT1 gene is used asor HPV detection
Weaknesses
analysis Low sensitivity , time consuming, relatively large
amounts of purified DNA
Southern blot and hybridization cannot use degraded DNA
Licensed and patented technologies
Wasn’t designed to genotyping individual
Lower amplification signals of some HPV genotypes
Contamination with previously amplified material can lead
to false positives
aptureW 2; PCR = Polymerase Chain Reaction.
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microarray chip, which is automatically scanned and
analyzed using the CheckScannerTM at both 532 and 635
nm, and the Check-ReportTM software, respectively
[31,32].
The main advantages of the PapilloCheckW assay
(Greiner Bio-One GmbH, Frickenhausen, Germany) is
HR/LR-HPV identification, and detection of multiple
infections, and may be considered a reliable screening
test [30]. However, this assay does not amplify HPV -35
and -53, the cost is still relatively high, and it requires
specific apparatus [33-35].Polymerase chain reaction (PCR)
The PCR-based techniques are highly sensitive, specific,
and widely used. In a conventional PCR, the thermo-
stable DNA polymerase recognizes and extends a pair of
oligonucleotide primers that flank the region of interest.
In the final process, the PCR can generate one billion
copies from a single double-stranded DNA molecule
after 30 cycles of amplification [36].
The HPV-PCR protocols use consensus primers such
as PGMY09/PGMY1 and GP5+/GP6+, which allow
amplification of a large number of HPV genotypes in a
single reaction. The primers target conserved regions of
the HPV genome, such as the L1 capsid gene [37]. After
amplification, the HPV genotypes can be determined
separately, using techniques such as restriction-fragment
length polymorphism (RFLP), linear probe assays, direct
sequencing, or genotype-specific primers [38]. Some
researchers have used a type-specific PCR, with primers
that amplify the long control region L1 and E6/E7 [39].
These PCR techniques also have some drawbacks,
mainly in competition for reagents, leading to false nega-
tive results for multiple type infections that are con-
tained in samples at lower copy numbers. Because of
this problem, the PCR method may not detect all the
HPV genotypes that are present in the sample. Another
downside is that multiple infections are not uncommon
[29]. Amplification of samples containing DNA from
more than one HPV genotype can lead to a much stron-
ger amplification of one of the sequences present, which
would complicate the detection of all genotypes in a
sample with multiple infections. Sometimes, additional,
labor-intensive procedures, such as sequencing or type-
specific PCR, are required [38].PCR-RFLP
Genotyping by PCR-RFLP allows the HPV to be typed,
and is easier and less expensive than sequencing [40].
The method is simple and robust, does not require
sophisticated equipment, and is particularly suited to
settings in which financial resources are limited [38,41].PCR-RFLP shows good discriminatory power by differ-
entiating the virus in HR or LR, and it is possible to
identify single or multiple infections. In this technique,
the amplified DNA is digested by restriction enzymes,
resulting in DNA fragments of various lengths. The
commonest restriction enzymes are BamHI, Dd6eI,
HaeIII, HinfI, PstI and RsaI [42]. However, Santiago
et al. used a single restriction enzyme, HpyCH4V, to de-
tect 21 HR- and 31 LR-HPV genotypes [43].Real-time PCR
This assay is a reliable, sensitive, and specific diagnostic
tool for detection and genotyping of targeted HPV geno-
types in tissue specimens [44] and cellular samples. The
advantages of this method are: (i) ability to detect viral
load; (ii) with the use of different fluorochromes that
emit fluorescence, as the PCR reaction proceeds, the
reactions can be performed in multiples and can amplify
different nucleic-acid targets; (iii) nucleic acids can be
detected even in very small concentrations, using a 7-log
dynamic range to extrapolate the viral load/concentra-
tion over the standard curve; and finally, (iv) it is ex-
tremely reproducible, rapid, and applicable to clinical
samples [45].Abbott real-time PCR
The Abbott Real-Time HR-HPV test is a novel assay
based on concurrent individual genotyping for HPV-16
/18 and pooled detection of 12 HPV genotypes: -31, -33,
-35, -39, -45, -51, -52, -56, -58, -59, -66 and -68 [44].COBASW 4800 HPV test
This test features automated sample preparation com-
bined with Real-Time PCR technology to detect 14 HR-
HPV. The PCR amplification and detection occur in a
single tube, (i) HPV -16, (ii) HPV -18, (iii) 12 HR (-31,
-33, -35, -39, -45, -51, -52, -56, -58, -59, -66, and -68) as
a pool, and (iv) β-globin as the control for extraction
and amplification adequacy [46].
The agreement between COBASW 4800 (Roche Mo-
lecular Systems, Pleasanton, CA, USA) and Real-Time
PCR was strong in a study that determined the reprodu-
cibility, involving a sequence of several consecutive
steps, both intra- and interlaboratory [46]. The assay is
easy to use because it is adapted for primary specimens,
and the results can be obtained approximately 4h after
the sample is received. COBASW 4800 fulfills all require-
ments as defined in the international guidelines to con-
sider it clinically validated for screening, and is reliable
in the detection of HR-HPV [47]. This test has been
clinically validated for ASC-US triage [48].
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The dideoxy chain-termination technique (Sanger tech-
nique) was first described for genome sequencing more
than three decades ago [49]. Fluorescently labeled
nucleotides were incorporated into Sanger sequencing,
and advances have led to increasing expansion and de-
velopment of high-quality, thorough sequencing [50,51].
However, it has not been validated for clinical use.
Similar to dideoxy sequencing methods, pyrosequen-
cing is applicable to any source of DNA or RNA that
can be amplified by PCR (blood, saliva, cell line, plasma,
serum, tissue, formalin-fixed paraffin-embedded sam-
ples, and whole genome-amplified DNA). The method is
based on the detection of the pyrophosphate released
during DNA synthesis, and has many advantages over
dideoxy sequencing for a wide range of applications that
require short-to medium-sequence stretches. The pri-
mary advantage is simplicity: the readout sequence itself
is obtained, rather than a fluorescent signal that must be
converted to a sequence. Second, it is faster and less ex-
pensive: savings result from its sequence-by-synthesis
process where a DNA sequence is read in real time, and
it is synthesized by addition of inexpensive, unlabeled
nucleotides; and finally, the method is uniquely quantita-
tive [52].
CLARTW human papillomavirus 2
The CLARTW Human Papillomavirus 2 (Genomica, Ma-
drid, Spain) methodology uses biotinylated primers that
amplify a 450 bp fragment within the HPV L1 region.
Co-amplification of an 892 bp region of the FTR gene
and a 1.202 bp fragment of a transformed plasmid pro-
vides a control to ensure DNA extraction adequacy and
PCR efficiency. Amplicons are detected by hybridization
in a low-density microarray containing triplicate DNA
probes specific for 35 HPV (-6, -11, -16, -18, -26, -31,
-33, -35, -39, -40, -42, -43, -44, -45, -51, -52, -53, -54,
-56, -58, -59, -61, -62, -66, -68, -70, -71, -72, -73, -81,
-82, -83, -84, -85 and -89). Semi-quantitative results can
be obtained in an automatic reader with highly compar-
able outcomes, showing excellent sensitivity, specificity,
and reproducibility [31].
INNO-LiPA
This assay genotypes all 14 HPV that are covered by
Real-Time [44]. INNO-LiPA (LiPA HBV GT; Innoge-
netics N.V., Ghent, Belgium) is based on the co-
amplification of the 65 bp region of the HPV L1 gene
and the 270 bp of the human HLA-DP1 gene using
SPF10 biotinylated primers, followed by genotyping
[53,54]. Some carcinogenic genotypes such as HPV-35,
-39, -52, -56 and -66 were not covered by this method,
and it was found to be the least effective genotyping for
HPV-42 and -59 [33].Although the majority of nucleic-acid amplification
methods can reliably detect HPV in cervical-swab speci-
mens, only a few, including Real-Time PCR, are poten-
tially suitable for archival clinical specimens, since they
target a relatively small portion of the HPV genome (less
than 160 bp). Therefore, the observed differences in in-
ternal control amplification efficacy between Real-Time
and INNO-LiPA can be attributed most reasonably to
the differences in target amplicon length: 136 bp vs. 270
bp, respectively [44]. This kit can be also used on sam-
ples taken with swabs, brushes, tampons, and lavage
[55,56].The Linear arrayW
The Linear ArrayW HPV Genotyping (Roche Molecular
Diagnostics, Pleasanton, CA, USA) is a PCR-based assay
coupled with a reverse line blot hybridization. This assay
allows the discrimination of 36 HPV, including 15 HR
(-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59,
-68, -73 and -82), 3 probable HR (-26, -53 and -66), 10
LR (-6, -11, -40, -42, -54, -61, -70,-72, -81 and -CP6108)
and 9 genotypes for which the risk is still undetermined
(-55, -62, -64, -67, -69, -71, -83, -84 and -IS39) [57].
The test uses biotinylated PGMY09/11 primers to
amplify a 450 bp fragment within the polymorphic L1
region of the HPV genome. Co-amplification of the 268
bp region of the human β-globin gene provides a control
to ensure DNA extraction adequacy and PCR efficiency.
The hybridization and detection of the amplified product
are performed with the Auto-LIPATM instrument (Inno-
genetics, Ghent, Belgium), which can process up to 30
strips simultaneously in a perfectly standardized fash-
ion. Colored signals on the strips are read by the naked
eye and interpreted according to the Linear ArrayW
reference guide. Equivocal results can be obtained for
HPV-52 when -33, -35 or -58 are also present, because
it is detected through a cross-hybridization probe for
these 4 HPV types. An additional, specific probe is
present on the strip to confirm the detection of HPV
-33, -35 and -58, but not of HPV -52 [34,58].Clinical arraysW HPV
This kit (Genomica SAU, Madrid, Spain) allows the de-
tection and genotyping of HPV. The DNA extraction
method is a modified procedure using absorption col-
umns. The kit employs biotinylated primers to define a
sequence of 451 nucleotides within the polymorphic L1
region of the HPV genome. A human cystic-fibrosis
transmembrane conductance regulator (CFTR) gene and
control plasmids are used to order to check both the
PCR procedure and the integrity of the DNA [23].
This also allows the detection of the 35 genotypes that
are individually associated with HR- (-16, -18, -26,-31,
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-70, -73, -82 and -85) or LR-HPV (-6, -11, -40, -42, -43,
-44, -54, -61, -62, -71, -72, -81, -83, -84 and -89). It is
possible to identify simple infections or co-infections
[23,59].Microplate colorimetric hybridization assay (MCHA)
The MCHA (Boehringer Mannheim, Germany) is a
method for identifying six HR-HPV (-16, -18, -31, -33,
-39 and -45) and is based on the amplification by PCR
of the 150 bp fragment within the L1 region by consen-
sus primers GP5+/6+, followed by colorimetric
hybridization to six type-specific probes on microwell
plates (ImmobilizerTM Amino Surface, Nunc, Roskilde,
Denmark) [35].
The MCHA showed very good agreement with Papil-
loCheckW for HPV-31, -33, -45 and higher sensitivity in
identifying HPV -16/18, but poor agreement for -39. To
improve MCHA for detection of other genotypes, probes
for HPV-35, -52, -56 and -58 should be included [35].HPV-mRNA detection
E6 and E7 are the main genes responsible for cell trans-
formation mediated by HR-HPV, and they modulate the
activities of cellular proteins that regulate the cell cycle
[60]. Thus, the presence of E6/E7 can be a specific mar-
ker for diagnosing precancerous lesions by HPV [61].
For this reason, the search for transcripts of E6/E7 could
increase the specificity and sensitivity of the tests in
screening for cervical lesions that have a greater chance
of progressing, compared with a simple detection of
HPV-DNA [11,19,62].
The main techniques used to detect mRNA for E6/E7
oncogenes are two commercial assays: PreTectW Proofer
and APTIMAW HPV Assay [63]. The chemistry is based
on transcription-mediated amplification of full-length
E6/E7 transcripts preempted by target capture.
The PretectW HPV-Proofer assay (NorChip AS, Klok-
karstua, Norway) detects E6/E7 mRNA from five HR-
HPV (-16, -18, -31,-33, and -45). Clinical studies have
shown high sensitivity. This assay is based on Real-Time
multiplex PCR and is more specific than HPV-PCR for
the detection of underlying HSIL (high-grade squamous
intraepithelial lesions) [19].
The APTIMAW HPV assay (Gen-Probe, San Diego,
CA, USA) detects HPV E6/E7 mRNA of the 14 HR (-16,
-18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, -66,
and -68), which provides better sensitivity than the
Proofer test, which detects only 5 HR-HPV [62]. This
assay has several advantages over the other HPV tests,
including: (i) detects HPV E6/E7 mRNA, which may be
a better marker of advanced disease than hc2; (ii) the
limit of detection is lower than the limits reported forother tests; (iii) it does not cross-react with LR-HPV
types tested in the current study; and (iv) it is compat-
ible with a fully automated processing system [19,62].
In addition, the oncoprotein E6 activates telomerase
reverse transcriptase (TERT) expression and causes cel-
lular immortalization [64]. Telomerase consists of sev-
eral subunits, including a structural RNA component
(hTR) that serves as a model during telomere elongation,
and a catalytic subunit (hTERT) that has reverse tran-
scriptase activity [65]. High levels of telomerase in tumor
cells invariably result from deregulated hTERT expres-
sion, and can be detected by quantitative Real-Time
PCR [66]. Also, studies have indicated that elevated
hTERT expression is a frequent event during cervical
carcinogenesis, and may be a valuable marker for pro-
gressive cervical lesions [67,68].
HPV viral load quantification and integration
HPV-DNA viral load
The association between the HPV viral load and cervical
lesions with malignant potential remains unclear. Many
studies of HPV load address the utility of predicting the
progression or severity of disease [69-72]. Lowe et al.
demonstrated differences in load between CIN I and
CIN II and between normal and all CIN, but not be-
tween CIN II and CIN III [72]. Thus, the results from
load histology and cytology are in agreement. Lowe et al.
also reported that the viral load declines in response to
therapy, and provides an acceptable alternative for deci-
sions to pursue further clinical trials [72]. However,
other studies have shown that viral load assessment had
no added value over cytology, and that testing for high
load levels may not be clinically useful, except in the
case of HPV -16 [70,71,73].
HPV viral load can be determined by Real-Time PCR
techniques. These techniques have been used for semi-
quantification in clinical samples, which can be also
determined by hc2 [74].
HPV-DNA integration
HPV-DNA is usually present in extrachromosomal or
episomal form in beginning cervical precursor lesions.
Integration of viral DNA frequently occurs in HSIL and
CC, and these lesions may often contain episomal and
integrated HPV-DNA at the same time [75]. During
HPV-DNA integration into the host cell, the viral gen-
ome usually breaks at E1 and/or E2 open reading frames
(ORFs), whereas the E6/E7 ORFs and long control re-
gion remain intact [76,77]. Loss of the E2 gene function
results in uncontrolled and increased expression of the
oncogenic proteins E6 and E7. A high copy number of
HPV-DNA directly contributes to HPV-DNA integration
and increased expression of E6 and E7 [75], and is
related to persistent HPV infection [74].
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earlier than the onset of morphological changes. Mo-
lecular events precede morphological features leading to
malignancy, and that integration does not always tem-
porally coincide with a high grade lesion. It is also pos-
sible that viral integration is not necessarily always
followed by immediate viral E1 and/or E2 expression
[78,79].
The main methods used for HPV integration detection
are PCR, fluorescence in situ hybridization, and Real-
Time PCR. The latter allows calculation of the ratio be-
tween the levels of E2 and E6/E7 HPV genes. When
there is HPV integration, the viral genome shows a 1:1
ratio between the E2 and E6/E7 genes [74].
Frequently, HPV integration by PCR uses E2-type-
specific primers in the HPV -16, -18 and/or E1-type-
specific primers in the HPV -16 [77,80]. The PCR
method is simple and easy to use, but it cannot be used
to determine the site of integration or to distinguish
between extrachromosomal or episomal forms, only
the pure integrated form [81]. Fluorescence in-situ
hybridization uses the locus-specific fluorescence
probes TERC (human telomerase gene-region 3q26)
and MYC gene (region 8q24) in cervical cytology spe-
cimens, and can be used to supplement the evaluation
of the integration of HPV by PCR [82].
Conclusions
CC develops over a long period, through precursor
lesions that may regress spontaneously without treat-
ment. The challenge of CC cytological screening is to
detect the lesions that have a high risk of progression.
Consequently, various biomarkers associated with the
risk of progression of this cancer have been investigated,
and most are associated with HR-HPV. Molecular tech-
niques are most commonly used for HPV testing, and
are the gold standard for diagnosing this viral infection.
Some of these methods may also be used for investiga-
tions of regional and country-based type-specific HPV
prevalence.
Cell infection by HPV is shown by changes in function
or in host gene expression, and the detection of these
changes may play a major role in the screening and
follow-up of infected patients. HPV-DNA viral load
quantification and integration, and E6/E7 expression are
promising biomarkers that can predict the progression
of lesions to CC, thus increasing the sensitivity of cyto-
logical screening. To date, there is no one ideal bio-
marker; however, overall, the combination of biomarkers
can contribute to early determination of CC, which can
be used to increase the positive predictive value of
current screening methods. Therefore, this review sum-
marizes current knowledge about detection methods for
HPV and related biomarkers. In spite of their value,molecular techniques still must become more rapid,
automated, and low-cost to be of practical use in low-
income populations and countries.
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